Introduction
Advances in supportive care have markedly improved survival for patients with acute respiratory syndrome (ARDS) 1 and sepsis. 2 However, both syndromes continue to be associated with high mortality and morbidity. 3, 4 Despite decades of clinical trials, eff ective pharmacotherapy for either syndrome remains elusive. 5, 6 A growing body of evidence suggests that cell-based therapy with stem or progenitor cells holds substantial therapeutic promise for a host of infl ammatory disorders, including ARDS and sepsis. 7, 8 Although several cell types, including endothelial progenitor cells and embryonic stem cells, are under investigation, this Review will focus on multipotent mesenchymal stem (or stromal) cells (MSCs).
We summarise the general properties of MSCs, explore how the paracrine eff ects of MSCs might aff ect ARDS and sepsis pathobiology, and review ongoing challenges in translational MSC research. We therefore provide a clinician-oriented framework for understanding of the expanding scientifi c literature for MSCs and how this research might eventually aff ect clinical care.
MSCs Overview
Originally isolated from bone marrow and termed fi broblastic colony-forming units, 9 MSCs are nonhaemopoietic stromal cells that have the ability to adhere to plastic in standard tissue culture, express characteristic cell-surface markers, and diff erentiate in vitro to osteoblasts, adipocytes, and chondroblasts. 10 MSCs can be isolated from most types of mesenchymal tissue, such as bone marrow, umbilical cord blood, placenta, and adipose tissue. 11 MSCs have several properties that make them attractive therapeutic candidates for treatment of acute disease. They are regarded as non-immunogenic because of their low constitutive expression of major histocompatibility complex (MHC) type I and the absence of both MHC type II and T-cell co-stimulatory molecules. This property theoretically allows for allogeneic transplantation without the need for HLA matching or immunosuppression. 11 Unlike embryonic stem cells, MSCs have low tumorigenicity and a short lifespan in vivo. 12 Finally, once isolated from host tissue, MSCs can be expanded rapidly ex vivo, which enables prompt clinical administration. 13 In view of these advantages, MSCs have become an active focus of investigation for a wide range of diseases, such as ischaemic cardiomyopathy, 14 chronic obstructive pulmonary disease, 15 acute neurological injuries, 16 graft-versus-host disease, 17 sepsis, and acute lung injury.
Mechanisms of potential benefi t
Understanding of the mechanisms by which MSCs promote tissue repair continues to progress. MSCs were initially thought to provide a niche for haemopoietic cells with their similarities to bone marrow stroma and ability to serve as feeder layers for haemopoietic cells in culture. 18 Initial research also focused on the ability of
• Despite advances in supportive care and decades of clinical trials, acute respiratory distress syndrome (ARDS) and sepsis remain associated with signifi cant morbidity and mortality.
• A growing body of literature suggests that multipotent mesenchymal stem cells (MSCs) hold signifi cant therapeutic promise for ARDS and sepsis.
• Although early research focused on the ability of MSCs to engraft at the site of tissue injury, newer evidence suggests that MSCs interact with host tissue partly through the release of soluble paracrine factors. These paracrine eff ects might modulate important pathobiological pathways in ARDS and sepsis.
• MSCs have been shown to have anti-infl ammatory eff ects on host tissue in preclinical models of ARDS and sepsis. Potential anti-infl ammatory paracrine factors include IL-1ra, TSG-6, IGF1, and prostaglandin E2.
• MSCs have been shown to preserve both vascular endothelial and alveolar epithelial barrier function in preclinical models of ARDS and sepsis.
• Preclinical models suggest that MSCs improve alveolar fl uid clearance, partly through the release of FGF7.
• MSCs have been reported to have antimicrobial eff ects, partly by increasing the phagocytic activity of host immune cells. These eff ects might be mediated by the release of lipocalin-2 and LL-37. MSCs might also prevent apoptosis of host cells, although this eff ect is not well understood.
• Experimental studies and ongoing clinical trials will both have important roles in the addressing of current gaps in knowledge.
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MSCs to structurally engraft at the site of tissue injury. [19] [20] [21] However, with refi ned research techniques, MSC engraftment seems to be a rare event 22, 23 of unclear physiological signifi cance. 13, 24 A growing number of studies have shown that MSCs have immunomodulatory and anti-infl ammatory eff ects despite minimum or absent engraftment. [25] [26] [27] [28] Consequently, research has shifted towards identifi cation of alternative pathways through which MSCs interact with host tissue, including interactions between cells, direct interactions with the host immune system, and mitochondrial transfer. The pathway with the most robust supporting evidence is the ability of MSCs to coordinate tissue repair through the release of soluble paracrine factors.
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This Review focuses on the paracrine eff ects of MSCs that modulate important pathobiological pathways in ARDS and sepsis, including infl ammation, endothelial and epithelial cell injury, alveolar fl uid clearance, antimicrobial activity, and apoptosis (fi gure). A summary of referenced literature is included in tables 1-4.
Figure:
Potential therapeutic eff ects of MSC therapy in ARDS and sepsis Protein-rich oedema fl uid and infl ammatory cells fi ll an injured alveolus as a result of a bacterial infection. MSCs have been shown in many preclinical studies to modify important pathobiological pathways in ARDS and sepsis through the release of paracrine factors. These modulatory eff ects include: exertion of antiinfl ammatory eff ects on host tissue; reduction of the permeability of the alveolar epithelium and vascular endothelium; improvement of alveolar fl uid clearance; improvement of the phagocytic activity of macrophages, monocytes, and neutrophils; and exertion of anti-apoptotic eff ects on host cells, although this pathway is not well characterised. Finally, MSCs might modulate tissue repair through direct mitochondrial transfer with host cells. How the route of MSC delivery aff ects the interaction between MSCs and host tissue is not well understood. Pathways depicted in the capillary and alveolus are not necessarily exclusive to that anatomical compartment, nor are they dependent on a certain route of MSC delivery. MSC=mesenchymal stem (stromal) cell. ARDS=acute respiratory distress syndrome. PGE2=prostaglandin E2. Disordered infl ammation has a central role in the pathogenesis of ARDS and sepsis. 53, 54 Substantial evidence from models of both lung injury and sepsis suggests that MSCs have an anti-infl ammatory eff ect on host tissue, partly through the release of paracrine factors.
Preclinical acute lung injury models
The anti-infl ammatory eff ects of MSCs have been reported in several models of acute lung injury. In a bleomycin lung injury model, intravenous MSCs delivered 6 h after injury normalised levels of proinfl ammatory cytokines when measured on day 14. 25 A paracrine mechanism was suggested by the small number of donor-derived cells that localised to the injured lung. Similarly, intratracheal delivery of MSCs reduced concentrations of proinfl ammatory cytokines and numbers of total cells and neutrophils in bronchoalveolar lavage (BAL) fl uid after injury with lipopolysaccharide (LPS), despite low levels of engraftment. 27, 30 Finally, treatment with MSC-conditioned media rather than actual MSCs has been noted to decrease BAL concentrations of cytokines and infl ammatory cells in ventilator-induced lung injury models in rats, which supports the presence of soluble anti-infl ammatory factors. 31 
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IL-1ra, which inhibits cytokine stimulation of a helper-Tlymphocyte line and suppresses macrophage production of the infl ammatory cytokine tumour necrosis factor α (TNFα) in an IL-1ra-dependent manner. 33 TSG-6, a potent anti-infl ammatory protein, has also been identifi ed as a potential paracrine factor. In a murine model of lung injury using LPS, MSCs upregulated expression of TSG-6, while decreasing cytokine levels and infl ammatory cell counts in BAL fl uid. 34 Knockdown of TSG-6 expression in MSCs nullifi ed most of these anti-infl ammatory eff ects when MSCs were given after injury. In support of these fi ndings, other studies show that intravenous administration of TSG-6 reduced alveolar concentrations of pro infl ammatory cytokines and improved survival in a bleomycin lung injury model. 55 TSG-6 also mediated the ability of MSCs to decrease infarct size and improve cardiac function after myocardial infarction in mice. 56 Finally, evidence suggests that IGF1 might have an important role in mediation of the anti-infl ammatory eff ects of MSCs. Ionescu and colleagues 35 reported that MSC-conditioned media restricted the alveolar infl ux of infl ammatory cells and improved the histological appearance of the lung when given after intratracheal LPS injury in an in-vivo mouse model of lung injury. MSC-conditioned media was also shown to promote diff erentiation of alveolar macrophages to an M2 antiinfl ammatory phenotype both in vitro and in vivo. 35 These anti-infl ammatory eff ects were partly reproduced in vitro and in vivo by the delivery of recombinant IGF1.
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Preclinical sepsis models
MSCs have also been shown to have anti-infl ammatory eff ects in several preclinical models of sepsis. Review intravenous LPS, 36 and ligation and puncture of the caecum; 37, 38 all despite limited or absent MSC engraftment. MSCs also seem to attenuate end-organ infl ammatory damage. 40 Intravenous MSCs improve lung histology and decrease concentrations of proinfl ammatory cytokines in BAL fl uid after infection, 28, 38 decrease concentrations of infl ammatory cytokines in cardiac tissue and improve cardiac function after intravenous LPS, 36 and also lower renal expression of proinfl ammatory cytokines and improve serological markers of kidney function after caecal ligation and puncture. 37 These eff ects occurred without substantial MSC localisation to the studied tissue, which suggests a paracrine mechanism.
As with lung injury models, investigators have used infection models to identify paracrine factors that might contribute to the observed benefi ts of MSCs. Recombinant TSG-6 reproduced the anti-infl ammatory eff ects of MSCs both in vivo and in vitro and blockage of TSG-6 synthesis by MSCs removed any observed antiinfl ammatory eff ects. 39 MSCs might also have a therapeutic benefi t in sepsis through reprogramming of host macrophages. In a series of well designed in-vivo experiments, Németh and colleagues 40 reported a therapeutic pathway in which MSCs exposed to TNFα or LPS increase production of prostaglandin E2 (PGE2). This pathway drives resident macrophages towards the M2 antiinfl ammatory phenotype, thereby increasing their production of the anti-infl ammatory cytokine interleukin 10 and causing decreased infl ammation and infl ammatory infi ltration into tissue. Production of PGE2 by MSCs with induction of an anti-infl ammatory phenotype in host immune cells has also been reported in vitro. 57 A summary of how the TSG-6 and PGE2 pathways contribute to our understanding of the antiinfl ammatory potential of MSCs was published by Prockop 41 MSCs decreased neutrophil infl ux and almost completely restored normal lung histology. Similar eff ects were reported when the model was extended to 10 h after injury and a higher bacterial load was used. Intrabronchial FGF7 replicated the reduction in neutrophil infl ux seen with MSCs, suggesting a potential role of FGF7 as a paracrine factor, possibly by reduction of endothelial and epithelial permeability.
Regulation of endothelial cell permeability
Vascular endothelial injury is a defi ning characteristic of both ARDS 59 and sepsis. 53 MSC therapy might help preserve endothelial barrier function in both syndromes (fi gure).
MSCs and conditioned media from a co-culture of endothelial cells and MSCs have been reported to decrease endothelial paracellular permeability and protect against infl ammatory disruption of barrier function in vitro by mobilisation of adherens junction proteins to cell membranes 42 and limitation of binding of infl ammatory cells to the endothelium. 43 In vivo, by use of a rat model of controlled haemorrhage, MSCs were seen to stabilise endothelial cells in haemorrhagic shock, partly by preservation of adherens junction and tight junction proteins. 43 MSCs were also shown to decrease vascular permeability in a mouse model of caecal ligation and puncture. 40 Finally, MSCs had benefi cial eff ects on endothelial cells in studies using ex-vivo perfused human lungs. 44 MSCs and MSCconditioned media, instilled intrabronchially 1 h after direct injury with E coli endotoxin, restored lung endothelial cell permeability to control levels. 44 
Regulation of epithelial cell permeability
The alveolar epithelial lining is composed of type I and type II alveolar cells. Alveolar epithelial cell injury contributes to several injury pathways in the development of ARDS, including loss of alveolar-capillary barrier integrity, dysregulated vectorial transport of alveolar fl uid, and disordered surfactant production. 59 MSCs might have a role in the preservation of epithelial cell function in ARDS.
In vitro, co-culture of MSCs with human alveolar type II cells exposed to cytomix (a mixture of the proinfl ammatory cytokines interleukin 1, TNFα, and interferon γ) restored epithelial cell protein permeability to pre-injury concentrations without the need for direct contact between cells, which suggests a therapeutic eff ect via a paracrine mechanism. 45 Angiopoietin-1 (ANG-1), an angiogenic factor known to stabilise endothelial cells during injury, 60 seemed to be at least partly responsible for this improvement. Similar fi ndings were described in an in-vitro study of rat alveolar epithelial cells injured with cytomix and hypoxia. 46 Exposure of the injured cells to MSCconditioned media restored normal epithelial barrier function. Concentrations of IL-1ra and PGE2 were noted to be statistically signifi cantly increased in MSCconditioned media after exposure to hypoxia and cytomix, suggesting their potential role as paracrine factors.
Increased alveolar fl uid clearance
Removal of alveolar oedema fl uid via vectorial transport across alveolar epithelial cells is crucial to recovery from acute lung injury. 61 A growing body of scientifi c literature suggests that MSCs improve alveolar fl uid clearance, partly through an FGF7-mediated mechanism.
In an in-vitro model of epithelial cell injury using rat alveolar epithelial cells exposed to cytomix and hypoxia, incubation of injured epithelial cells with MSCconditioned media preserved epithelial sodium transport and prevented a decrease in apical expression of αENaC subunits (one of the three subunits that form the epithelial sodium channel). 46 These benefi ts did not occur in FGF7-depleted MSC-conditioned media. Similar fi ndings were reported in an in-vitro model with human alveolar type II cells exposed to cytomix. 44 Incubation of injured epithelial cells with MSCs preserved net fl uid transport and partly restored apical membrane expression of αENaC subunits. Blockage of MSC FGF7 expression prevented this therapeutic eff ect, again suggesting that FGF7 is a probable epithelial-protective paracrine factor.
The ability of MSCs to restore alveolar fl uid clearance has also been noted in ex-vivo perfused human lungs. Intrabronchial administration of both MSCs and MSCconditioned media to lungs injured with E coli endotoxin has been shown to reduce lung water and normalise alveolar fl uid clearance.
44 FGF7-depleted media had a negligable eff ect on alveolar fl uid clearance, whereas the addition of recombinant FGF7 to the media restored its therapeutic benefi t. Similar improvements in alveolar fl uid clearance with MSCs were noted when ex-vivo lungs were directly injured with live bacteria. 41 Finally, in a 2014 study 47 with perfused lungs that were rejected for transplant, intravenous administration of MSCs normalised alveolar fl uid clearance. Pretreatment of the perfused lung with an FGF7-blocking antibody statistically signifi cantly reduced this eff ect.
Antimicrobial eff ects
Despite their immunosuppressive properties, MSCs have been reported to have several antimicrobial eff ects. Since infection is the most common cause of ARDS, 54 these antimicrobial eff ects raise important therapeutic possibilities for ARDS and sepsis.
In murine infection models, MSCs reduce bacterial levels in the alveoli, blood, and spleen. 37, 38, [48] [49] [50] [51] This antibacterial eff ect is partly mediated by improved phagocytic activity of host immune cells such as macrophages, 38, 41 monocytes, 48 neutrophils, 49 and ITGAMpositive cells (monocytes, macrophages, and neutrophils). 38 Studies using ex-vivo human lungs have reported similar fi ndings. MSCs reduced alveolar bacterial counts and improved alveolar macrophage phagocytosis after direct bacterial injury. 41 This eff ect seems to be partly mediated by FGF7, because the use of an FGF7-neutralising antibody nullifi ed the antimicrobial eff ects of MSCs both in vitro and ex vivo. 41 Alveolar fl uid from lungs treated with MSCs was noted to have increased antimicrobial activity against E coli in vitro, suggesting the presence of a secreted antimicrobial factor.
In addition to FGF7, several other antimicrobial paracrine factors have been identifi ed. In vitro, mouse MSCs have been reported to increase the production of the antimicrobial peptide lipocalin-2 51 and human MSCs produce LL-37 50 in response to infectious and infl ammatory stimuli. Use of a blocking antibody for both of these peptides nullifi ed the antimicrobial eff ects of MSCs in vivo.
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Anti-apoptotic eff ects
Apoptosis of both immune and structural cells is an important component of ARDS and sepsis pathogenesis. 53, 62 A potential eff ect of MSC therapy is the ability to restrict the apoptosis of host cells. In vitro, both MSCs and MSC supernatant have been reported to have notable anti-apoptotic eff ects on resting and activated neutrophils. 52 This eff ect does not require direct contact between cells and seems to be mediated partly by MSC production of the anti-apoptotic cytokine interleukin 6 (fi gure). 52 MSC production of FGF7 has also been postulated to inhibit apoptosis of monocytes, leading to increased bacterial killing. 41 Future research will hopefully illuminate the extent and signifi cance of this pathway.
Alternative pathways
Although the paracrine pathways described undoubtedly have a major role in mediation of the interactions between MSCs and host tissue, other potential pathways have been identifi ed. Research investigating these pathways will probably contribute substantially to a more nuanced understanding of the mechanisms underlying MSC therapy.
Clear evidence exists that marrow-derived MSCs have a crucial role in regulation of the haemopoietic microenvironment in bone marrow 63 and can help to direct the creation of vascular networks in host tissue. 64 However, it is unclear to what extent the benefi cial eff ects of MSC therapy for non-skeletal pathology might be secondary to this ability to interact with nascent capillary networks. 64 Evidence also suggests that MSCs might modulate endogenous repair mechanisms and aff ect the activity of host progenitor cells. 65 MSCs express high levels of genes essential to the regulation of haemopoietic stem cells, 66 stimulate proliferation of endogenous cardiac progenitor cells during experimental myocardial infarction, 67 and possibly increase the number of lung progenitor cells in response to injury. 65 Finally, MSCs seem able to aff ect tissue repair through the delivery of extracellular vesicles 68, 69 and direct mitochondrial transfer. 70 Although a detailed exploration of this scientifi c literature is beyond the scope of this review, table 5 shows a brief overview of several representative studies.
Challenges and future directions
In the past two decades, substantial progress has been made in the understanding of how MSCs interact with
Summary Extracellular vesicles
Bruno et al 68, 71 Microvesicles derived from human MSCs had protective eff ects in both in-vitro and in-vivo acute kidney injury models Lee et al 72 Intravenous administration of MSC-derived exosomes decreased the infl ux of infl ammatory mediators and inhibited vascular remodelling and pulmonary hypertension in a murine model of hypoxia-induced pulmonary hypertension
Zhou et al 73 Renal capsule injection of exosomes isolated from human umbilical cord blood MSCs attenuated blood and histological markers of acute kidney injury in an in-vivo rat model; exosomes also limited apoptosis and oxidative stress in vitro Zhu et al 69 Intratracheal and intravenous delivery of microvesicles isolated from human MSCs reduced infl ammation and lung water in a murine lung injury model using Escherichia coli endotoxin; in-vitro microvesicles restored epithelial cell barrier function after infl ammatory injury
Mitochondrial transfer
Islam et al 70 In a murine lung injury model using intratracheal LPS, MSCs attached to alveoli and formed nanotubes through which mitochondria-containing microvesicles were transferred to the alveolar epithelium; this transfer ameliorated lung injury
Ahmad et al 74 In-vitro and in-vivo evidence of mitochondrial transfer between MSCs and injured epithelial cells via nanotubes which rescues epithelial cells from infl ammation and improves host bioenergetics Li et al 75 Mitochondrial transfer between human MSCs derived from induced pluripotent stem cells and lung epithelial cells injured by cigarette smoke both in vitro and in an in-vivo rat model
MSC=mesenchymal stem (stromal) cell. LPS=lipopolysaccharide. 10 and even medicinal signalling cells. 78 Scientists continue to disagree over the most appropriate defi nition of MSCs with many following the criteria set out by the International Society for Cellular Therapy, 10 and others advocating the more conservative defi nition of marrow-derived cells able to generate a heterotopic ossicle in vivo. 79 MSCs are probably not true stem cells because they seem to have their therapeutic eff ects through mechanisms unrelated to their progenitor function and have not been convincingly shown to regenerate non-skeletal tissue. 79, 80 Beyond clarifi cation of the phenotypes of MSCs, substantial research eff orts are needed to fully identify the eff ects of MSCs when given to an injured host. As noted, our understanding of the paracrine eff ects of MSCs, their ability to interact with injured host cells, and their eff ect on host angiogenesis and endogenous repair is incomplete. Although the behaviour of MSCs is undoubtedly aff ected by the local microenvironment, 79, 81 this eff ect cannot be reliably quantifi ed and predicted. 13 Murine MSCs, although used in many preclinical models, have unique tumorigenicity and culture requirements, which raises questions about their ability to truly replicate the behaviour of human-derived MSCs. 13 Researchers also probably do not fully appreciate the inherent diff erences between MSCs cultured from diff erent donors 82 and are only beginning to appreciate how age might aff ect MSC function. 83 Finally, we remain unable to answer defi nitively basic mechanistic questions, such as how MSCs have a therapeutic eff ect on non-pulmonary tissue when given intravenously. MSCs become trapped in the lung after intravenous administration, yet have benefi cial eff ects in traumatic brain injury and myocardial infarction (supporting the presence of secreted paracrine factors). 80 All of these gaps in knowledge underscore a pressing need to validate candidate mechanisms in reproducible in-vivo models and for improved characterisation of bioactive factors and their mode of action. 79 Two studies 84, 85 in sheep models of ARDS have lent support to the safety and potential effi cacy of MSC therapy. A small randomised trial of adipose-derived MSCs in 12 patients with ARDS in China is the fi rst to suggest that MSCs can be safely given to patients with ARDS. 86 In the USA, a phase 1/2 clinical trial of a single infusion of allogeneic bone marrow-derived human MSCs in early ARDS, sponsored by the National Heart Lung and Blood Institute (NCTO1775774 and NCT02097641), is underway, while a Canadian phase 1 trial of MSC therapy for patients with septic shock (Cellular Immunotherapy for Septic Shock) is in the planning phase.
As the critical care community begins to focus on the use of MSCs in clinical trials, 8 researchers have to deal with a number of questions regarding drug safety, reproducibility, and clinical trial design. An emphasis on the need to ensure that preparations of MSCs used in clinical trials are of a standardised and verifi able quality is at the centre of many thoughtful reviews on the subject. 13, 64, 79, 80, 87, 88 This requirement is challenging because many variables, such as temperature and culture density, can all aff ect MSC phenotype. 88 Furthermore, MSCs can be cultured from multiple sites, including adipose tissue, bone marrow, and muscle. Researchers do not yet understand how these cells diff er biologically nor are they able to reliably quantify how these MSCs diff er in their interactions with an injured host. Attempts to generalise the safety profi le and therapeutic eff ects of a unique cell preparation should therefore be interpreted with caution. To help address these issues, experienced centres are now issuing MSC preparations prepared with standardised protocols. 80 Although MSC therapy has been used in early clinical trials without apparent safety issues, 15, 86, 89 care should be taken when monitoring short-term and long-term safety. For trials including patients with heterogeneous diseases such as ARDS and sepsis, thoughtful inclusion criteria and reliable endpoints should be considered to obtain clinically meaningful results. 87 Finally, many issues remain with regard to clinical trial design such as determination of the optimum mode and timing of MSC delivery, and identifi cation of which patients with ARDS or sepsis are most likely to benefi t from experimental therapy. 8 
Search strategy and selection criteria
Articles for this Review were identifi ed by searches of Medline, Current Contents, PubMed, and references from relevant articles using the search terms "MSC", "mesenchymal stem cells", "mesenchymal stromal cells", "marrow stromal cells", "acute respiratory distress syndrome", "acute lung injury", and "sepsis". Experts in the fi eld were asked for additional or unpublished research not identifi ed in the original search. We including only articles published in English between January, 1968 and August, 2014. 
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As the list of identifi ed bioactive factors and extracellular vesicles secreted by MSCs continues to expand, the isolation of these molecules and investigation of their clinical use separate from MSCs (cell-free therapy) will be of increasing interest. 90 As with MSC therapy, a push for expedited clinical trials will need to be balanced with a focus on basic and translational research to improve the understanding of the in-vitro and in-vivo behaviour of cell-free therapies. Attention will need to be given to the full identifi cation and classifi cation of the bioactive molecules secreted by MSCs, determination of how cell-free therapies diff er in both safety and effi cacy (conditioned media vs isolated bioactive factors vs exosomes), and tests of whether potential therapies should be given as single drugs or in combination. Finally, new safety concerns will need to be carefully investigated, including the ability of exosomes to act as delivery vehicles for viruses and cancer proteins.
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Conclusion
The clinical use of MSCs has been variably described as a therapy likely to change the practice of medicine 78 and one inappropriately cast as a panacea for all disorders without the necessary supporting in-vivo research. 79 The many preclinical models reviewed suggest that MSC therapy holds substantial therapeutic promise for ARDS and sepsis, especially with the scarcity of viable pharmacological treatments. However, encouraging preclinical fi ndings do not guarantee effi cacy in clinical trials. Experimental studies and ongoing randomised trials will have an important role in the clarifi cation of the therapeutic potential of MSCs and furthering our understanding of how MSCs interact with host tissue.
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